GSK tar­gets a new in­di­ca­tion for Nu­cala, flags PhI­II suc­cess for a rare dis­ease

Glax­o­SmithK­line may soon have a new mar­ket for its asth­ma drug Nu­cala (mepolizum­ab). The phar­ma gi­ant says that their Phase III study of the drug for a rare dis­ease char­ac­ter­ized by in­flam­ma­tion of small blood ves­sel walls came through with fly­ing col­ors.

In­ves­ti­ga­tors at GSK, work­ing with a team at the NIH, say the drug hit both co-pri­ma­ry end­points as well as all sec­ondary end­points in their late-stage study of the drug in pa­tients suf­fer­ing from Eosinophilic Gran­u­lo­mato­sis with Polyangi­itis, or EG­PA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER